Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 13/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 10/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807491 | 0.88 | CCR3 (0.49) | CCR3DRD3TMEM97CCR2CD274 | |
| SCHEMBL6807489 | 0.84 | SLC2A1 (0.52) | DRD3CCR2DRD2DRD4 | |
| SCHEMBL6806794 | 0.82 | CCR3 (0.49) | CCR3DRD3TMEM97CCR2CD274 | |
| SCHEMBL5937412 | 0.82 | DRD3 (0.46) | CCR3DRD3TMEM97DRD2HTR2A | |
| SCHEMBL5937249 | 0.82 | DRD3 (0.46) | CCR3DRD3TMEM97CCR2DRD2 | |
| SCHEMBL6807861 | 0.81 | SLC6A3 (0.36) | DRD3DRD2HTR2A | |
| SCHEMBL5937378 | 0.81 | CCR2 (0.43) | CCR3DRD3TMEM97CCR2CD274 | |
| SCHEMBL5937233 | 0.80 | DRD3 (0.44) | CCR3DRD3TMEM97CCR2CD274 | |
| SCHEMBL5937391 | 0.79 | DRD3 (0.42) | CCR3DRD3TMEM97CCR2DRD2 | |
| SCHEMBL1542994 | 0.79 | CCR3 (0.42) | CCR3DRD3TMEM97CCR2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072865-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | claimed |
| US-20040072865-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
| EP-1351935-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055495-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072865-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | CCR3 290/4885DRD3 222/4885TMEM97 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.